Suven Life Sciences has informed that it enclosed News Release of the company titled ‘Suven Life Sciences announces three poster presentations on Samelisant (SUVN-G3031), including global Phase-3, AWAKE Narcolepsy Study at the SLEEP-2026 Annual Meeting being held at Baltimore, USA’.
The above information is a part of company’s filings submitted to BSE.